Sanofi plots strategy for India; Amgen declares fourth-quarter dividend;

@FiercePharma: India's pharma industry is the country's 2nd-best at making billionaires. More | Follow @FiercePharma

> Sanofi ($SNY) is weighing its strategy in India, now that it has launched the first locally manufactured insulin pen. Report

> Amgen's ($AMGN) board of directors approved a $0.36-per-share dividend to be paid Dec. 7. Report

> Actavis won FDA approval for its version of the Valeant Pharmaceuticals ($VRX) heart drug Tiazac, which treats high blood pressure. Report

> Canadians may find their favorite over-the-counter cold and flu medications in short supply because of ongoing supply problems at a Novartis ($NVS) plant. Report

> The Canadian pharmacy group Jean Coutu saw profits rise on growth at its generic drugmaker Pro Doc. Report

> Congressional staffers expect FDA Commissioner Margaret Hamburg to remain in her post if President Obama is re-elected. Report

Medical Device News

 @FierceMedDev: As BSX has implied, the job cuts are coming. More | Follow @FierceMedDev

 @MarkHFierce: Not only is angel investing recovering, but much of it seems to be hitting medical device startups. More | Follow @MarkHFierce

 @DamianFierce: Four former Synthes execs have been effectively blacklisted from the life sciences industry. More | Follow @DamianFierce

> J&J's Cordis touts stent for femoral artery disease. Story

> Medical devices drive the start of an angel investor rebound. Item

> Quest Diagnostics slashing 400-600 jobs to save $65M. More

Biotech News

 @FierceBiotech: New special report: Top diabetes drug pipelines of 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Kythera IPO prices at high end of range (I don't write that very often). More | Follow @JohnCFierce

 @RyanMFierce: GSK will decide whether to grant access to the ID-less patient data based on scientific merit. Sounds subjective, but progress nonetheless. | Follow @RyanMFierce

> Sanofi argues its R&D costs are too high, but backs down on Toulouse. Story

> Will GlaxoSmithKline's transparency pledge force pharma rivals to open up? Article

Pharma Manufacturing News

> Novasep investing in another API expansion. News

> Auctus Pharma API plant in India catches fire. Report

> Merck opens $21M Jakarta packaging plant. Story

Vaccines News

> GSK, Aeras partner for TB vaccine trial. More

> Merck taps Vaxxas for Nanopatch vaccine delivery. Story

> Pfizer's Prevnar 13 posts positive late-stage data. Report

> Takeda snaps up LigoCyte for $60M. Item

And Finally... Wired magazine joined the lobbying for a drug-development prize to replace current patent-system incentives. Report

Suggested Articles

Merck & Co. joined the pack in 2018 by hiring Jim Scholefield as its first chief digital officer. Now, less than two years in, he's moving on.

Teva is counting on Austedo for growth amid challenges elsewhere, and this week, the drug failed two trials in Tourette Syndrome.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.